RevenueThe total money the company brought in from sales, before subtracting any costs.
$0βΌ β100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$10MβΌ β17.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$9Mβ² +194.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
6.3Mβ² +4.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4MβΌ β$3M YoY
StockOtter Β· stockotter.space
About EXICURE INC
Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)